Show simple item record

dc.rights.licenceAtribución-NoComercial 4.0 Internacional*
dc.date.accessioned2020-05-06T13:05:13Z
dc.date.available2020-05-06T13:05:13Z
dc.date.created2008
dc.identifierhttps://www.nejm.org/doi/full/10.1056/NEJMoa0807646spa
dc.identifier.issn0028-4793 / 1533-4406 (Electrónico)spa
dc.identifier.urihttp://hdl.handle.net/10554/49071
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.languagespaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceNew England Journal of Medicine; Vol. 359 Núm. 21 (2008)spa
dc.titleRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinspa
dc.typeinfo:eu-repo/semantics/article
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.description.quartilescopusQ1spa
dc.identifier.doihttps://doi.org/10.1056/NEJMoa0807646spa
dc.description.paginas2195-2207spa
dc.format.soportePapel / Electrónicospa
dc.description.abstractenglishBACKGROUND Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment. METHODS We randomly assigned 17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo and followed them for the occurrence of the combined primary end point of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. RESULTS The trial was stopped after a median follow-up of 1.9 years (maximum, 5.0). Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. The rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56; 95% confidence interval [CI], 0.46 to 0.69; P<0.00001), with corresponding rates of 0.17 and 0.37 for myocardial infarction (hazard ratio, 0.46; 95% CI, 0.30 to 0.70; P=0.0002), 0.18 and 0.34 for stroke (hazard ratio, 0.52; 95% CI, 0.34 to 0.79; P=0.002), 0.41 and 0.77 for revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.00001), 0.45 and 0.85 for the combined end point of myocardial infarction, stroke, or death from cardiovascular causes (hazard ratio, 0.53; 95% CI, 0.40 to 0.69; P<0.00001), and 1.00 and 1.25 for death from any cause (hazard ratio, 0.80; 95% CI, 0.67 to 0.97; P=0.02). Consistent effects were observed in all subgroups evaluated. The rosuvastatin group did not have a significant increase in myopathy or cancer but did have a higher incidence of physician-reported diabetes. CONCLUSIONS In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. (ClinicalTrials.gov number, NCT00239681. opens in new tab.)spa
dc.type.localArtículo de revistaspa
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución-NoComercial 4.0 Internacional